Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Antimicrob Chemother ; 54(4): 840-3, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15347634

RESUMO

OBJECTIVE: To compare the bacteriological and clinical efficacy of three treatments for uncomplicated cystitis in ambulatory pre-menopausal women: ciprofloxacin 250 mg orally twice daily for 3 days, trimethoprim/sulfamethoxazole 160/800 mg orally twice daily for 7 days, and norfloxacin 400 mg orally twice daily for 7 days. MATERIALS AND METHODS: A total of 455 women were randomly assigned to three treatment groups: 151 received ciprofloxacin, 150 received trimethoprim/sulfamethoxazole, and 154 received norfloxacin. Bacteriological cure and clinical resolution were evaluated 5-9 days and 4-6 weeks after completion of treatment. RESULTS: There was no significant difference among the three treatment groups: overall efficacy ranged from 78.5% for the trimethoprim/sulfamethoxazole group, to 84.5% for the ciprofloxacin group. The highest overall incidence of drug-related adverse effects occurred in the trimethoprim/sulfamethoxazole patients. CONCLUSIONS: These data indicate that a 3 day treatment with ciprofloxacin is at least as clinically and bacteriologically effective as 7 day treatments with trimethoprim/sulfamethoxazole and norfloxacin for uncomplicated lower urinary tract infections.


Assuntos
Antibacterianos/uso terapêutico , Ciprofloxacina/uso terapêutico , Norfloxacino/uso terapêutico , Sulfametoxazol/uso terapêutico , Trimetoprima/uso terapêutico , Infecções Urinárias/tratamento farmacológico , Antibacterianos/administração & dosagem , Ciprofloxacina/administração & dosagem , Esquema de Medicação , Feminino , Humanos , América Latina , Norfloxacino/administração & dosagem , Pré-Menopausa , Estudos Prospectivos , Sulfametoxazol/administração & dosagem , Fatores de Tempo , Resultado do Tratamento , Trimetoprima/administração & dosagem
2.
Rev Invest Clin ; 56(5): 572-9, 2004.
Artigo em Espanhol | MEDLINE | ID: mdl-15776859

RESUMO

UNLABELLED: The objective of the present study was to determine the efficacy and safety of a fixed dose of vardenafil in the treatment of patients with erectile dysfunction (ED). MATERIAL AND METHODS: This was an open label, prospective and multicentric trial. After a 4-week wash out period, all patients received 20 mg of vardenafil given on demand for 12 weeks. Primary efficacy variables were the erectile function domain of the International Index of Erectile Function (IIEF), answers to questions 2 and 3 of the Sexual Encounter Profile (SEP) and the Global Assessment Question (GAQ). All adverse events were recorded and reported. RESULTS: 229 patients were screened. 177 received at least one dose of vardenafil and were included in the safety analysis. Mean age was 54.4 years old. Etiology of ED was organic or mixed in 77% of the patients. Erectile function domain of the IIEF changed from a basal mean score of 14.8 to 25.5 at the end of the study. 80.5% of the patients reported erections of rigidity and duration enough for satisfactory sexual intercourse and 93.3% improved their erections at the end of the study. Adverse events were mild to moderate and the most common were headache, dyspepsia, rhinitis and facial flushing. The drop out rate due to adverse events was 1.7%. CONCLUSIONS: This multicenter study confirms the high efficacy of this new phosphodiesterase type 5 inhibitor, vardenafil. There was a low rate of discontinuations due to adverse events and a favorable safety profile. The results of this study are similar to the results of other studies conducted in other parts of the world.


Assuntos
Disfunção Erétil/tratamento farmacológico , Imidazóis/uso terapêutico , Inibidores de Fosfodiesterase/uso terapêutico , Piperazinas/uso terapêutico , Sulfonas/uso terapêutico , Triazinas/uso terapêutico , Adulto , Idoso , Humanos , Masculino , México , Pessoa de Meia-Idade , Estudos Prospectivos , Inquéritos e Questionários , Dicloridrato de Vardenafila
3.
Rev. sanid. mil ; 51(1): 30-4, ene.-feb. 1997. tab
Artigo em Espanhol | LILACS | ID: lil-227333

RESUMO

El parto pretérmino constituye la principal causa de morbimortalidad neonatal, se han tratado de implementar diversas medidas terapéuticas y preventivas sin que su incidencia haya disminuido. Se realizó un estudio comparativo del uso de salbutamol y óxido nítrico en el manejo de las pacientes con amenaza de parto pretérmino en el periodo de agosto de 1995 a mayo de 1996, evaluándose variables demográficas, efectos hemodinámicos, efectos en el producto, vía de parto, complicaciones asociadas y periodo de prolongación del embarazo, sin que se encontrará diferencia estadísticamente significativa. Se concluye que el óxido nítrico puede emplearse como alternativa de tratamiento


Assuntos
Humanos , Feminino , Gravidez , Adulto , Colo do Útero/efeitos dos fármacos , Idade Gestacional , Albuterol/uso terapêutico , Trabalho de Parto Prematuro/tratamento farmacológico , Hemodinâmica , Óxido Nítrico/uso terapêutico , Tocólise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...